Understanding current therapies in metastatic melanoma
No Thumbnail Available
Date
2016
Journal Title
Journal ISSN
Volume Title
Publisher
SOC MEDICA SANTIAGO
Abstract
Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen- 4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
Description
Keywords
CTLA-4 Antigen, Melanoma, Molecular Targeted Therapy, Pembrolizumab, Programmed Cell Death 1 Receptor, BRAF INHIBITOR RESISTANCE, OPEN-LABEL, DRUG-RESISTANCE, MEK INHIBITION, PHASE-II, IMPROVED SURVIVAL, RANDOMIZED-TRIAL, SOLID TUMORS, VEMURAFENIB, NIVOLUMAB